Cargando…
Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
Olodaterol (BI 1744 CL) is a novel, once-daily long-acting β(2)-agonist (LABA) designed with the aim of improving β(2)-adrenoreceptor selectivity and intrinsic activity. Phase III pivotal trials have documented that olodaterol Respimat Soft Mist inhaler 5 μg induces fast onset of bronchodilation, co...
Autores principales: | Matera, Maria Gabriella, Ora, Josuel, Cazzola, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675639/ https://www.ncbi.nlm.nih.gov/pubmed/26676161 http://dx.doi.org/10.2147/TCRM.S73581 |
Ejemplares similares
-
The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis
por: Rogliani, Paola, et al.
Publicado: (2017) -
Striving for optimal bronchodilation: focus on olodaterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016) -
Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019) -
The future of bronchodilation: looking for new classes of bronchodilators
por: Cazzola, Mario, et al.
Publicado: (2019) -
Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences
por: Cazzola, Mario, et al.
Publicado: (2023)